In summary, TNFRSF1A inhibition appears to have a dampening effect on some aspects leucocyte biology and is protective for pneumonia and the autoimmune condition ankylosing spondylitis but conversely displays a risk-increasing relationship with inflammatory-related conditions like Multiple sclerosis, suggesting that more analysis of this candidate therapeutic target is warranted. The gene discussed is TNFRSF1A; the disease is ankylosing spondylitis.